Biodexa Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Biodexa Pharmaceuticals şirketinin toplam hissedar öz sermayesi £8.7M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £14.0M ve £5.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£5.06m
Eşitlik	UK£8.73m
Toplam yükümlülükler	UK£5.24m
Toplam varlıklar	UK£13.97m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 5MP1 'nin kısa vadeli varlıkları ( £7.5M ) kısa vadeli yükümlülüklerini ( £3.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 5MP1 şirketinin kısa vadeli varlıkları ( £7.5M ) uzun vadeli yükümlülüklerini ( £1.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 5MP1 borçsuzdur.

Borcun Azaltılması: 5MP1 şirketinin 5 yıl önce borç/öz sermaye oranı 4.4% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 5MP1 son raporlanan serbest nakit akışına göre 7 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: 5MP1 serbest nakit akışı tahminlerine göre 8 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Biodexa Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule

Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements

Recent updates

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023)

Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009969 million.

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009968 million.

Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data

Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ At 12 Months in Familial Adenomatous Polyposis (Fap)

Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis

Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: UK£8.00 loss per share (vs UK£620 loss in FY 2022)

New minor risk - Financial data availability

Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

New major risk - Financial position

Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million.

New major risk - Financial position

Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano)

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs)

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015

Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule

Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements

Biodexa Pharmaceuticals Plc announced that it has received $3.320388 million in funding

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Biodexa Pharmaceuticals Plc (NasdaqCM:BDRX) entered into non-binding letter of intent to acquire Varian Biopharmaceuticals Inc. for $3.7 million.

Full year 2022 earnings released: UK£0.077 loss per share (vs UK£1.36 loss in FY 2021)

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin